Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments
Patients with cancer (PC) are at high risk of acquiring COVID-19 and can develop more serious complications. Deeper understanding of vaccines immunogenicity in this population is crucial for adequately planning vaccines programs. The ONCOVac study aimed to comprehensively assess the immunogenicity o...
Saved in:
Published in | European journal of cancer (1990) Vol. 166; pp. 229 - 239 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.05.2022
Elsevier Science Ltd The Author(s). Published by Elsevier Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Patients with cancer (PC) are at high risk of acquiring COVID-19 and can develop more serious complications. Deeper understanding of vaccines immunogenicity in this population is crucial for adequately planning vaccines programs. The ONCOVac study aimed to comprehensively assess the immunogenicity of mRNA-1273 vaccine in terms of humoral and cellular response.
We conducted a prospective, single-center study including patients with solid tumours treated with cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i), immunotherapy (IT) or chemotherapy (CT). Patients were enrolled previously to vaccination with mRNA-1273. We also involved health care workers (HCW) to serve as a control group. We took blood samples before first dose administration (BL), after first dose (1D), and after second dose (2D). The primary objective was to compare the rate and magnitude of T cell response after second dose whereas safety and humoral response were defined as secondary objectives. We also collected patient reported outcomes after both the first and second vaccine dose and a six-month follow-up period to diagnose incident COVID-19 cases was planned.
The rate of specific anti-S serologic positivity (anti-S IgG cut-off point at 7,14 BAU/mL) was significantly higher in HCW compared to PC after 1D (100% versus 83.8%; p = 0.04), but similar after 2D (100% versus 95.8%; p = 0.5). This difference after 1D was driven by PC treated with CT (100% versus 64.5%; p = 0.001). Cellular response after 2D was significantly lower in PC than in HCW for both CD4+ (91.7% versus 59.7%; p = 0.001) and CD8+ (94.4% versus 55.6%; p < 0.001) T cells. We found a difference on pre-existing CD4+ T cell response in HCW comparing to PC (36% and 17%, p = 0.03); without difference in pre-existing CD8+ T cell response (31% and 23%, p = 0.5). After excluding patients with pre-existing T cell response, PC achieved even lower CD4+ (50.9% versus 95.5%, p < 0.001) and CD8+ (45.5% versus 95.5%, p < 0.001) T cell response compared with HCW. Regarding safety, PC reported notably more adverse events than HCW (96.6% versus 69.2%, p < 0.001).
We demonstrated that PC showed a similar humoral response but a lower T cell response following two doses of mRNA-1273 vaccination. Further studies are needed to complement our results and determine the implication of low T cell response on clinical protection of PC against COVID-19.
•Cancer patients showed lower humoral response after one dose of mRNA-1273 vaccine.•Humoral response achieves similar levels after full vaccination.•Cellular response was significantly lower in cancer patients compared to controls. |
---|---|
AbstractList | Patients with cancer (PC) are at high risk of acquiring COVID-19 and can develop more serious complications. Deeper understanding of vaccines immunogenicity in this population is crucial for adequately planning vaccines programs. The ONCOVac study aimed to comprehensively assess the immunogenicity of mRNA-1273 vaccine in terms of humoral and cellular response.
We conducted a prospective, single-center study including patients with solid tumours treated with cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i), immunotherapy (IT) or chemotherapy (CT). Patients were enrolled previously to vaccination with mRNA-1273. We also involved health care workers (HCW) to serve as a control group. We took blood samples before first dose administration (BL), after first dose (1D), and after second dose (2D). The primary objective was to compare the rate and magnitude of T cell response after second dose whereas safety and humoral response were defined as secondary objectives. We also collected patient reported outcomes after both the first and second vaccine dose and a six-month follow-up period to diagnose incident COVID-19 cases was planned.
The rate of specific anti-S serologic positivity (anti-S IgG cut-off point at 7,14 BAU/mL) was significantly higher in HCW compared to PC after 1D (100% versus 83.8%; p = 0.04), but similar after 2D (100% versus 95.8%; p = 0.5). This difference after 1D was driven by PC treated with CT (100% versus 64.5%; p = 0.001). Cellular response after 2D was significantly lower in PC than in HCW for both CD4+ (91.7% versus 59.7%; p = 0.001) and CD8+ (94.4% versus 55.6%; p < 0.001) T cells. We found a difference on pre-existing CD4+ T cell response in HCW comparing to PC (36% and 17%, p = 0.03); without difference in pre-existing CD8+ T cell response (31% and 23%, p = 0.5). After excluding patients with pre-existing T cell response, PC achieved even lower CD4+ (50.9% versus 95.5%, p < 0.001) and CD8+ (45.5% versus 95.5%, p < 0.001) T cell response compared with HCW. Regarding safety, PC reported notably more adverse events than HCW (96.6% versus 69.2%, p < 0.001).
We demonstrated that PC showed a similar humoral response but a lower T cell response following two doses of mRNA-1273 vaccination. Further studies are needed to complement our results and determine the implication of low T cell response on clinical protection of PC against COVID-19.
•Cancer patients showed lower humoral response after one dose of mRNA-1273 vaccine.•Humoral response achieves similar levels after full vaccination.•Cellular response was significantly lower in cancer patients compared to controls. Patients with cancer (PC) are at high risk of acquiring COVID-19 and can develop more serious complications. Deeper understanding of vaccines immunogenicity in this population is crucial for adequately planning vaccines programs. The ONCOVac study aimed to comprehensively assess the immunogenicity of mRNA-1273 vaccine in terms of humoral and cellular response. We conducted a prospective, single-center study including patients with solid tumours treated with cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i), immunotherapy (IT) or chemotherapy (CT). Patients were enrolled previously to vaccination with mRNA-1273. We also involved health care workers (HCW) to serve as a control group. We took blood samples before first dose administration (BL), after first dose (1D), and after second dose (2D). The primary objective was to compare the rate and magnitude of T cell response after second dose whereas safety and humoral response were defined as secondary objectives. We also collected patient reported outcomes after both the first and second vaccine dose and a six-month follow-up period to diagnose incident COVID-19 cases was planned. The rate of specific anti-S serologic positivity (anti-S IgG cut-off point at 7,14 BAU/mL) was significantly higher in HCW compared to PC after 1D (100% versus 83.8%; p = 0.04), but similar after 2D (100% versus 95.8%; p = 0.5). This difference after 1D was driven by PC treated with CT (100% versus 64.5%; p = 0.001). Cellular response after 2D was significantly lower in PC than in HCW for both CD4+ (91.7% versus 59.7%; p = 0.001) and CD8+ (94.4% versus 55.6%; p < 0.001) T cells. We found a difference on pre-existing CD4+ T cell response in HCW comparing to PC (36% and 17%, p = 0.03); without difference in pre-existing CD8+ T cell response (31% and 23%, p = 0.5). After excluding patients with pre-existing T cell response, PC achieved even lower CD4+ (50.9% versus 95.5%, p < 0.001) and CD8+ (45.5% versus 95.5%, p < 0.001) T cell response compared with HCW. Regarding safety, PC reported notably more adverse events than HCW (96.6% versus 69.2%, p < 0.001). We demonstrated that PC showed a similar humoral response but a lower T cell response following two doses of mRNA-1273 vaccination. Further studies are needed to complement our results and determine the implication of low T cell response on clinical protection of PC against COVID-19. Introduction Patients with cancer (PC) are at high risk of acquiring COVID-19 and can develop more serious complications. Deeper understanding of vaccines immunogenicity in this population is crucial for adequately planning vaccines programs. The ONCOVac study aimed to comprehensively assess the immunogenicity of mRNA-1273 vaccine in terms of humoral and cellular response. Methods We conducted a prospective, single-center study including patients with solid tumours treated with cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i), immunotherapy (IT) or chemotherapy (CT). Patients were enrolled previously to vaccination with mRNA-1273. We also involved health care workers (HCW) to serve as a control group. We took blood samples before first dose administration (BL), after first dose (1D), and after second dose (2D). The primary objective was to compare the rate and magnitude of T cell response after second dose whereas safety and humoral response were defined as secondary objectives. We also collected patient reported outcomes after both the first and second vaccine dose and a six-month follow-up period to diagnose incident COVID-19 cases was planned. Results The rate of specific anti-S serologic positivity (anti-S IgG cut-off point at 7,14 BAU/mL) was significantly higher in HCW compared to PC after 1D (100% versus 83.8%; p = 0.04), but similar after 2D (100% versus 95.8%; p = 0.5). This difference after 1D was driven by PC treated with CT (100% versus 64.5%; p = 0.001). Cellular response after 2D was significantly lower in PC than in HCW for both CD4+ (91.7% versus 59.7%; p = 0.001) and CD8+ (94.4% versus 55.6%; p < 0.001) T cells. We found a difference on pre-existing CD4+ T cell response in HCW comparing to PC (36% and 17%, p = 0.03); without difference in pre-existing CD8+ T cell response (31% and 23%, p = 0.5). After excluding patients with pre-existing T cell response, PC achieved even lower CD4+ (50.9% versus 95.5%, p < 0.001) and CD8+ (45.5% versus 95.5%, p < 0.001) T cell response compared with HCW. Regarding safety, PC reported notably more adverse events than HCW (96.6% versus 69.2%, p < 0.001). Conclusion We demonstrated that PC showed a similar humoral response but a lower T cell response following two doses of mRNA-1273 vaccination. Further studies are needed to complement our results and determine the implication of low T cell response on clinical protection of PC against COVID-19. |
Author | Rosero, Diana Serrano, Juan J. Cortés, Alfonso Romero, Beatriz Olmedo, María E. Martin, Adrián Gion, María Vallejo, Alejandro Casado, José L. López Miranda, Elena Guerra Alia, Eva Carrato, Alfredo Fuentes Mateos, Raquel Saavedra, Cristina Gajate, Pablo Alonso Gordoa, Teresa Lage, Yolanda Fernández, María Velasco, Héctor Molina Cerrillo, Javier Martínez Jáñez, Noelia Reguera Puertas, Pablo Chamorro, Jesús Longo, Federico Martínez Delfrade, Íñigo Soria Rivas, Ainara Rodríguez-Domínguez, Mario J. |
Author_xml | – sequence: 1 givenname: Alfonso surname: Cortés fullname: Cortés, Alfonso organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 2 givenname: José L. orcidid: 0000-0002-7639-8591 surname: Casado fullname: Casado, José L. organization: Infectious Disease Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 3 givenname: Federico orcidid: 0000-0003-0902-2188 surname: Longo fullname: Longo, Federico organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 4 givenname: Juan J. orcidid: 0000-0003-4126-7150 surname: Serrano fullname: Serrano, Juan J. organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 5 givenname: Cristina orcidid: 0000-0002-1063-2306 surname: Saavedra fullname: Saavedra, Cristina organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 6 givenname: Héctor surname: Velasco fullname: Velasco, Héctor organization: Laboratory of Immunovirology, Infectious Diseases Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 7 givenname: Adrián surname: Martin fullname: Martin, Adrián organization: Laboratory of Immunovirology, Infectious Diseases Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 8 givenname: Jesús surname: Chamorro fullname: Chamorro, Jesús organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 9 givenname: Diana surname: Rosero fullname: Rosero, Diana organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 10 givenname: María surname: Fernández fullname: Fernández, María organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 11 givenname: María surname: Gion fullname: Gion, María organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 12 givenname: Noelia surname: Martínez Jáñez fullname: Martínez Jáñez, Noelia organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 13 givenname: Ainara surname: Soria Rivas fullname: Soria Rivas, Ainara organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 14 givenname: Teresa surname: Alonso Gordoa fullname: Alonso Gordoa, Teresa organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 15 givenname: Íñigo orcidid: 0000-0002-7574-8991 surname: Martínez Delfrade fullname: Martínez Delfrade, Íñigo organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 16 givenname: Yolanda surname: Lage fullname: Lage, Yolanda organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 17 givenname: Elena surname: López Miranda fullname: López Miranda, Elena organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 18 givenname: María E. surname: Olmedo fullname: Olmedo, María E. organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 19 givenname: Pablo surname: Reguera Puertas fullname: Reguera Puertas, Pablo organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 20 givenname: Pablo orcidid: 0000-0001-5156-7080 surname: Gajate fullname: Gajate, Pablo organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 21 givenname: Javier orcidid: 0000-0003-4616-0598 surname: Molina Cerrillo fullname: Molina Cerrillo, Javier organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 22 givenname: Eva surname: Guerra Alia fullname: Guerra Alia, Eva organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 23 givenname: Raquel surname: Fuentes Mateos fullname: Fuentes Mateos, Raquel organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 24 givenname: Beatriz orcidid: 0000-0002-2813-740X surname: Romero fullname: Romero, Beatriz organization: Microbiology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 25 givenname: Mario J. orcidid: 0000-0002-1783-9318 surname: Rodríguez-Domínguez fullname: Rodríguez-Domínguez, Mario J. organization: Microbiology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 26 givenname: Alejandro surname: Vallejo fullname: Vallejo, Alejandro email: alejandro.vallejo@salud.madrid.org organization: Laboratory of Immunovirology, Infectious Diseases Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain – sequence: 27 givenname: Alfredo surname: Carrato fullname: Carrato, Alfredo email: acarrato@telefonica.net organization: Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35316750$$D View this record in MEDLINE/PubMed |
BookMark | eNp9UdtqGzEQFSWlcdL-QB-KoM_rjrSrvUApGJNewLSQpH0Vs9pxosUruZLs0r-vFiehfSkMzMO5zHDOBTtz3hFjrwUsBYj63bik0eBSgpRLyCOaZ2wh2qYroFXyjC2gU13RQtWds4sYRwBo2gpesPNSlaJuFCxY3NjJJhr4LTe02_FAce9dJJ48v1ld3xRr_6OQfLr-uuJHNMY64jh5d8f3mCy5FPkvm-65QWcoZLkhe7QZHux2SyETHqEUCNM0K16y51vcRXr1sC_Z949Xt-vPxebbpy_r1aYwVVumQhghJQ6oBuxgqKApO4mmHyohUJW9lNAjSEVkVC_6TmFFCnsoS4W1MLIsL9mHk-_-0E80mHw74E7vg50w_NYerf4XcfZe3_mjbtucX1tng7cPBsH_PFBMevSH4PLPWtZ1Drfp6iaz5Illgo8x0PbpggA9F6VHPRel56I05BGz6M3fvz1JHpvJhPcnAuWEjpaCjibnbWiwOeSkB2__5_8HzRGnfw |
CitedBy_id | crossref_primary_10_3390_cancers14225630 crossref_primary_10_1016_j_ijid_2022_07_050 crossref_primary_10_1080_21645515_2022_2119763 crossref_primary_10_1080_21645515_2024_2357424 crossref_primary_10_3390_cancers14184464 crossref_primary_10_3389_fimmu_2022_1062136 crossref_primary_10_3390_vaccines10071068 crossref_primary_10_1158_1078_0432_CCR_22_2185 crossref_primary_10_12688_f1000research_110268_2 crossref_primary_10_3390_v15071439 crossref_primary_10_3389_fonc_2023_1280416 crossref_primary_10_1093_infdis_jiad174 crossref_primary_10_1016_j_esmoop_2022_100587 crossref_primary_10_3389_fmicb_2022_1002748 crossref_primary_10_1136_bmjonc_2023_000054 |
Cites_doi | 10.1093/jncics/pkaa102 10.1002/cti2.1341 10.1056/NEJMoa2035389 10.1016/j.breast.2021.08.017 10.1016/j.cell.2020.05.015 10.1056/NEJMoa2101544 10.1016/j.annonc.2021.04.019 10.1016/j.ccell.2021.07.016 10.1016/j.ejca.2020.08.011 10.1126/sciimmunol.abj1750 10.1016/S1473-3099(20)30831-8 10.1016/j.ejca.2021.08.007 10.1016/j.annonc.2021.08.1550 10.1016/S0140-6736(20)32661-1 10.1016/j.ccell.2021.06.009 10.1016/j.xcrm.2021.100355 10.1038/s41591-021-01240-w 10.1200/GO.20.00225 10.1186/s13045-021-01099-x 10.1016/j.ccell.2021.01.001 10.1038/s41591-021-01542-z 10.1126/sciadv.abg4081 10.1016/j.annonc.2021.01.068 10.1038/s41586-020-2550-z 10.1158/2159-8290.CD-20-1817 10.1016/j.ejca.2021.12.011 10.1016/S1470-2045(21)00213-8 10.1016/S0140-6736(21)00234-8 10.1128/JCM.01746-21 10.1016/j.ejca.2021.08.035 10.1056/NEJMoa2034577 10.1016/j.esmoop.2021.100274 10.1001/jamaoncol.2021.2675 10.1016/j.ejca.2021.03.033 10.1016/j.ejca.2021.10.014 10.1016/S1470-2045(21)00155-8 10.1001/jamaoncol.2021.2155 10.1016/j.annonc.2021.10.014 10.1038/s41590-020-0782-6 10.1172/JCI141206 |
ContentType | Journal Article |
Copyright | 2022 The Author(s) Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. Copyright Elsevier Science Ltd. May 2022 2022 The Author(s) 2022 |
Copyright_xml | – notice: 2022 The Author(s) – notice: Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. – notice: Copyright Elsevier Science Ltd. May 2022 – notice: 2022 The Author(s) 2022 |
DBID | 6I. AAFTH CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TO 7U7 C1K H94 K9. NAPCQ 5PM |
DOI | 10.1016/j.ejca.2022.02.017 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management |
DatabaseTitleList | MEDLINE AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-0852 |
EndPage | 239 |
ExternalDocumentID | 10_1016_j_ejca_2022_02_017 35316750 S0959804922001095 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29G 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6I. 6PF 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAFTH AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAWTL AAXUO ABBQC ABFNM ABGSF ABJNI ABLJU ABLVK ABMAC ABMZM ABOCM ABUDA ABXDB ABYKQ ACDAQ ACIUM ACPRK ACRLP ADBBV ADEZE ADMUD ADUVX AEBSH AEHWI AEKER AENEX AEVXI AFCTW AFFNX AFKWA AFRAH AFRHN AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DOVZS DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IHE J1W K-O KOM LCYCR M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSU SSZ T5K UV1 WUQ X7M XPP Z5R ZA5 ZGI ZXP ~G- AAXKI AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TO 7U7 C1K H94 K9. NAPCQ 5PM |
ID | FETCH-LOGICAL-c483t-1c122ada5da90d407392acbd411a53b220ba025eec5b1b95a4e5ab0335a61c233 |
IEDL.DBID | AIKHN |
ISSN | 0959-8049 |
IngestDate | Tue Sep 17 21:15:35 EDT 2024 Fri Sep 13 09:30:42 EDT 2024 Thu Sep 26 16:29:57 EDT 2024 Sat Sep 28 08:16:41 EDT 2024 Fri Feb 23 02:40:54 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | SARS-CoV-2 Humoral response Solid tumours Vaccination Cellular response |
Language | English |
License | This is an open access article under the CC BY license. Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c483t-1c122ada5da90d407392acbd411a53b220ba025eec5b1b95a4e5ab0335a61c233 |
Notes | Equal contribution. |
ORCID | 0000-0001-5156-7080 0000-0003-4616-0598 0000-0002-1783-9318 0000-0003-4126-7150 0000-0002-7639-8591 0000-0003-0902-2188 0000-0002-2813-740X 0000-0002-7574-8991 0000-0002-1063-2306 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0959804922001095 |
PMID | 35316750 |
PQID | 2669597967 |
PQPubID | 2047469 |
PageCount | 11 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8885286 proquest_journals_2669597967 crossref_primary_10_1016_j_ejca_2022_02_017 pubmed_primary_35316750 elsevier_sciencedirect_doi_10_1016_j_ejca_2022_02_017 |
PublicationCentury | 2000 |
PublicationDate | 2022-05-01 |
PublicationDateYYYYMMDD | 2022-05-01 |
PublicationDate_xml | – month: 05 year: 2022 text: 2022-05-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Oxford |
PublicationTitle | European journal of cancer (1990) |
PublicationTitleAlternate | Eur J Cancer |
PublicationYear | 2022 |
Publisher | Elsevier Ltd Elsevier Science Ltd The Author(s). Published by Elsevier Ltd |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier Science Ltd – name: The Author(s). Published by Elsevier Ltd |
References | Baden, El Sahly, Essink, Kotloff, Frey, Novak (bib3) 2021; 384 Giannakoulis, Papoutsi, Siempos (bib8) 2020 Ribas, Sengupta, Locke, Zaidi, Campbell, Carethers (bib11) 2021; 11 Cavanna, Citterio, Biasini, Madaro, Bacchetta, Lis (bib15) 2021; 157 Ehmsen, Asmussen, Jeppesen, Nilsson, Østerlev, Vestergaard (bib22) 2021; 39 Saker, Escuret, Pitiot, Massardier-Pilonchéry, Paul, Mokdad (bib29) 2022; 60 Saini, Tagliamento, Lambertini, McNally, Romano, Leone (bib9) 2020; 139 Salazar, Kuchipudi, Christensen, Eagar, Yi, Zhao (bib42) 2020; 130 Shroff, Chalasani, Wei, Pennington, Quirk, Schoenle (bib32) 2021 Mansi, Spehner, Daguindau, Bouiller, Almotlak, Stein (bib25) 2021; 150 (bib1) 2020 Addeo, Shah, Bordry, Hudson, Albracht, Di Marco (bib13) 2021; 39 Voysey, Clemens, Madhi, Weckx, Folegatti, Aley (bib4) 2021; 397 Yatim, Boussier, Tetu, Smith, Bruel, Charbit (bib38) 2021; 7 Xia, Zhang, Wang, Wang, Yang, Gao (bib7) 2021; 21 Zagouri, Terpos, Fiste, Liontos, Briasoulis, Katsiana (bib33) 2021; 60 Venkatesulu, Chandrasekar, Girdhar, Advani, Sharma, Elumalai (bib10) 2021; 5 Tarke, Sidney, Methot, Yu, Zhang, Dan (bib26) 2021; 2 Grifoni, Weiskopf, Ramirez, Mateus, Dan, Moderbacher (bib27) 2020; 181 van der Veldt, Oosting, Dingemans, Fehrmann, GeurtsvanKessel, Jalving (bib34) 2021; 27 Waissengrin, Agbarya, Safadi, Padova, Wolf (bib41) 2021; 22 Shroff, Chalasani, Wei, Pennington, Quirk, Schoenle (bib21) 2021; 27 Painter, Mathew, Goel, Apostolidis, Pattekar, Kuthuru (bib35) 2021 Logunov, Dolzhikova, Shcheblyakov, Tukhvatulin, Zubkova, Dzharullaeva (bib6) 2021; 397 Goshen-Lago, Waldhorn, Holland, Szwarcwort-Cohen, Reiner-Benaim, Shachor-Meyouhas (bib23) 2021; 7 Polack, Thomas, Kitchin, Absalon, Gurtman, Lockhart (bib2) 2020; 383 Sadoff, Gray, Vandebosch, Cárdenas, Shukarev, Grinsztejn (bib5) 2021; 384 Terpos, Zagouri, Liontos, Sklirou, Koutsoukos, Markellos (bib19) 2021 Le Bert, Tan, Kunasegaran, Tham, Hafezi, Chia (bib28) 2020; 584 Shepherd, Fendler, Au, Byrne, Wilkinson, Wu (bib39) 2021; 32 Geers, Shamier, Bogers, den Hartog, Gommers, Nieuwkoop (bib37) 2021; 6 Corti, Antonarelli, Scotté, Spano, Barrière, Michot (bib30) 2022; 33 Barrière, Chamorey, Adjtoutah, Castelnau, Mahamat, Marco (bib14) 2021 Shmueli, Itay, Margalit, Berger, Halperin, Jurkowicz (bib18) 2021; 157 Casado, Haemmerle, Vizcarra, Rodriguez-Dominguez, Velasco, Velasco (bib40) 2021; 10 Barrière, Carles, Audigier-Valette, Re, Adjtoutah, Seitz-Polski (bib43) 2022; 162 Abdul-Jawad, Baù, Alaguthurai, Del Molino Del Barrio, Laing, Hayday (bib24) 2021; 39 Monin, Laing, Muñoz-Ruiz, McKenzie, Del Molino Del Barrio, Alaguthurai (bib20) 2021; 22 Garassino, Vyas, de Vries, Kanesvaran, Giuliani, Peters (bib12) 2021 Becerril-Gaitan, Vaca-Cartagena, Ferrigno, Mesa-Chavez, Barrientos-Gutiérrez, Tagliamento (bib31) 2022; 160 Peeters, Verbruggen, Teuwen, Vanhoutte, Vande Kerckhove, Peeters (bib17) 2021; 6 Massarweh, Eliakim-Raz, Stemmer, Levy-Barda, Yust-Katz, Zer (bib16) 2021; 7 Peng, Mentzer, Liu, Yao, Yin, Dong (bib36) 2020; 21 Goshen-Lago (10.1016/j.ejca.2022.02.017_bib23) 2021; 7 Garassino (10.1016/j.ejca.2022.02.017_bib12) 2021 Peeters (10.1016/j.ejca.2022.02.017_bib17) 2021; 6 Casado (10.1016/j.ejca.2022.02.017_bib40) 2021; 10 Xia (10.1016/j.ejca.2022.02.017_bib7) 2021; 21 Polack (10.1016/j.ejca.2022.02.017_bib2) 2020; 383 Logunov (10.1016/j.ejca.2022.02.017_bib6) 2021; 397 Shroff (10.1016/j.ejca.2022.02.017_bib21) 2021; 27 Waissengrin (10.1016/j.ejca.2022.02.017_bib41) 2021; 22 Tarke (10.1016/j.ejca.2022.02.017_bib26) 2021; 2 Grifoni (10.1016/j.ejca.2022.02.017_bib27) 2020; 181 Yatim (10.1016/j.ejca.2022.02.017_bib38) 2021; 7 Peng (10.1016/j.ejca.2022.02.017_bib36) 2020; 21 Saini (10.1016/j.ejca.2022.02.017_bib9) 2020; 139 Barrière (10.1016/j.ejca.2022.02.017_bib43) 2022; 162 van der Veldt (10.1016/j.ejca.2022.02.017_bib34) 2021; 27 Barrière (10.1016/j.ejca.2022.02.017_bib14) 2021 Corti (10.1016/j.ejca.2022.02.017_bib30) 2022; 33 Becerril-Gaitan (10.1016/j.ejca.2022.02.017_bib31) 2022; 160 Abdul-Jawad (10.1016/j.ejca.2022.02.017_bib24) 2021; 39 Saker (10.1016/j.ejca.2022.02.017_bib29) 2022; 60 Zagouri (10.1016/j.ejca.2022.02.017_bib33) 2021; 60 Cavanna (10.1016/j.ejca.2022.02.017_bib15) 2021; 157 Shepherd (10.1016/j.ejca.2022.02.017_bib39) 2021; 32 (10.1016/j.ejca.2022.02.017_bib1) 2020 Terpos (10.1016/j.ejca.2022.02.017_bib19) 2021 Painter (10.1016/j.ejca.2022.02.017_bib35) 2021 Giannakoulis (10.1016/j.ejca.2022.02.017_bib8) 2020 Geers (10.1016/j.ejca.2022.02.017_bib37) 2021; 6 Monin (10.1016/j.ejca.2022.02.017_bib20) 2021; 22 Ribas (10.1016/j.ejca.2022.02.017_bib11) 2021; 11 Ehmsen (10.1016/j.ejca.2022.02.017_bib22) 2021; 39 Le Bert (10.1016/j.ejca.2022.02.017_bib28) 2020; 584 Shroff (10.1016/j.ejca.2022.02.017_bib32) 2021 Massarweh (10.1016/j.ejca.2022.02.017_bib16) 2021; 7 Salazar (10.1016/j.ejca.2022.02.017_bib42) 2020; 130 Shmueli (10.1016/j.ejca.2022.02.017_bib18) 2021; 157 Baden (10.1016/j.ejca.2022.02.017_bib3) 2021; 384 Mansi (10.1016/j.ejca.2022.02.017_bib25) 2021; 150 Venkatesulu (10.1016/j.ejca.2022.02.017_bib10) 2021; 5 Addeo (10.1016/j.ejca.2022.02.017_bib13) 2021; 39 Sadoff (10.1016/j.ejca.2022.02.017_bib5) 2021; 384 Voysey (10.1016/j.ejca.2022.02.017_bib4) 2021; 397 |
References_xml | – volume: 157 start-page: 441 year: 2021 end-page: 449 ident: bib15 article-title: COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: seropositivity and safety. A prospective observational study in Italy publication-title: Eur J Cancer contributor: fullname: Lis – volume: 6 start-page: 100274 year: 2021 ident: bib17 article-title: Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment publication-title: ESMO Open contributor: fullname: Peeters – volume: 384 start-page: 403 year: 2021 end-page: 416 ident: bib3 article-title: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine publication-title: N Engl J Med contributor: fullname: Novak – start-page: 579 year: 2021 end-page: 581 ident: bib12 article-title: The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate publication-title: Ann Oncol: Off J Eur Soc Med Oncol contributor: fullname: Peters – volume: 10 start-page: 1 year: 2021 end-page: 8 ident: bib40 article-title: T-cell response after first dose of BNT162b2 SARS-CoV-2 vaccine among healthcare workers with previous infection or cross-reactive immunity publication-title: Clin Transl Immunol contributor: fullname: Velasco – volume: 397 start-page: 671 year: 2021 end-page: 681 ident: bib6 article-title: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia publication-title: Lancet (London, England) contributor: fullname: Dzharullaeva – start-page: 86 year: 2021 ident: bib19 article-title: Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors publication-title: J Hematol Oncol contributor: fullname: Markellos – volume: 39 start-page: 1034 year: 2021 end-page: 1036 ident: bib22 article-title: Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer publication-title: Cancer Cell contributor: fullname: Vestergaard – volume: 7 start-page: 1507 year: 2021 end-page: 1513 ident: bib23 article-title: Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer publication-title: JAMA Oncol contributor: fullname: Shachor-Meyouhas – start-page: 799 year: 2020 end-page: 808 ident: bib8 article-title: Effect of cancer on clinical outcomes of patients with COVID-19: a meta-analysis of patient data publication-title: JCO Global Oncology contributor: fullname: Siempos – volume: 60 start-page: 58 year: 2021 end-page: 61 ident: bib33 article-title: SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors publication-title: Breast (Edinburgh, Scotland) contributor: fullname: Katsiana – volume: 32 start-page: S1129 year: 2021 ident: bib39 article-title: 1557O Adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients: the CAPTURE study publication-title: Ann Oncol contributor: fullname: Wu – start-page: 1053 year: 2021 end-page: 1055 ident: bib14 article-title: Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors publication-title: Ann Oncol: Off J Eur Soc Med Oncol contributor: fullname: Marco – volume: 181 start-page: 1489 year: 2020 end-page: 1501.e15 ident: bib27 article-title: Targets of T Cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals publication-title: Cell contributor: fullname: Moderbacher – volume: 384 start-page: 2187 year: 2021 end-page: 2201 ident: bib5 article-title: Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19 publication-title: N Engl J Med contributor: fullname: Grinsztejn – year: 2020 ident: bib1 publication-title: WHO COVID-19 dashboard – volume: 27 start-page: 2002 year: 2021 end-page: 2011 ident: bib21 article-title: Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors publication-title: Nat Med contributor: fullname: Schoenle – volume: 139 start-page: 43 year: 2020 end-page: 50 ident: bib9 article-title: Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies publication-title: Eur J Cancer (Oxford, England: 1990) contributor: fullname: Leone – volume: 162 start-page: 182 year: 2022 end-page: 193 ident: bib43 article-title: Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: should humoral responses be monitored? A position article publication-title: Eur J Cancer (Oxford, England: 1990) contributor: fullname: Seitz-Polski – volume: 2 start-page: 100355 year: 2021 ident: bib26 article-title: Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals publication-title: Cell Rep Med contributor: fullname: Dan – volume: 33 start-page: 158 year: 2022 end-page: 168 ident: bib30 article-title: Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review publication-title: Ann Oncol: Off J Eur Soc Med Oncol contributor: fullname: Michot – volume: 7 start-page: 1133 year: 2021 end-page: 1140 ident: bib16 article-title: Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer publication-title: JAMA Oncol contributor: fullname: Zer – year: 2021 ident: bib32 article-title: Immune responses to COVID-19 mRNA vaccines in patients with solid tumors on active, immunosuppressive cancer therapy publication-title: medRxiv: Preprint Server for Health Sciences contributor: fullname: Schoenle – volume: 397 start-page: 99 year: 2021 end-page: 111 ident: bib4 article-title: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK publication-title: Lancet contributor: fullname: Aley – volume: 6 year: 2021 ident: bib37 article-title: SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees publication-title: Sci Immunol contributor: fullname: Nieuwkoop – volume: 11 start-page: 233 year: 2021 end-page: 236 ident: bib11 article-title: Priority Covid-19 vaccination for patients with cancer while vaccine supply is limited publication-title: Cancer Discov contributor: fullname: Carethers – volume: 22 start-page: 765 year: 2021 end-page: 778 ident: bib20 article-title: Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study publication-title: Lancet Oncol contributor: fullname: Alaguthurai – volume: 150 start-page: 1 year: 2021 end-page: 9 ident: bib25 article-title: Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients publication-title: Eur J Cancer (Oxford, England: 1990) contributor: fullname: Stein – volume: 39 start-page: 257 year: 2021 end-page: 275.e6 ident: bib24 article-title: Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients publication-title: Cancer Cell contributor: fullname: Hayday – volume: 160 start-page: 243 year: 2022 end-page: 260 ident: bib31 article-title: Immunogenicity and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after coronavirus disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis publication-title: Eur J Cancer (Oxford, England: 1990) contributor: fullname: Tagliamento – volume: 27 start-page: 568 year: 2021 end-page: 569 ident: bib34 article-title: COVID-19 vaccination: the VOICE for patients with cancer publication-title: Nat Med contributor: fullname: Jalving – volume: 21 start-page: 1336 year: 2020 end-page: 1345 ident: bib36 article-title: Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 publication-title: Nat Immunol contributor: fullname: Dong – volume: 383 start-page: 2603 year: 2020 end-page: 2615 ident: bib2 article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine publication-title: N Engl J Med contributor: fullname: Lockhart – volume: 584 start-page: 457 year: 2020 end-page: 462 ident: bib28 article-title: SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls publication-title: Nature contributor: fullname: Chia – year: 2021 ident: bib35 article-title: Rapid induction of antigen-specific CD4 publication-title: bioRxiv contributor: fullname: Kuthuru – volume: 60 year: 2022 ident: bib29 article-title: Evaluation of commercial anti-SARS-CoV-2 antibody assays and comparison of standardized titers in vaccinated health care workers publication-title: J Clin Microbiol contributor: fullname: Mokdad – volume: 157 start-page: 124 year: 2021 end-page: 131 ident: bib18 article-title: Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy - a single centre prospective study publication-title: Eur J Cancer (Oxford, England: 1990) contributor: fullname: Jurkowicz – volume: 39 start-page: 1091 year: 2021 end-page: 1098.e2 ident: bib13 article-title: Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer publication-title: Cancer Cell contributor: fullname: Di Marco – volume: 21 start-page: 39 year: 2021 end-page: 51 ident: bib7 article-title: Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial publication-title: Lancet Infect Dis contributor: fullname: Gao – volume: 5 start-page: 1 year: 2021 end-page: 11 ident: bib10 article-title: A systematic review and meta-analysis of cancer patients affected by a novel coronavirus publication-title: JNCI Cancer Spectr contributor: fullname: Elumalai – volume: 7 start-page: 1 year: 2021 end-page: 13 ident: bib38 article-title: Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection publication-title: Sci Adv contributor: fullname: Charbit – volume: 22 start-page: 581 year: 2021 end-page: 583 ident: bib41 article-title: Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors publication-title: Lancet Oncol contributor: fullname: Wolf – volume: 130 start-page: 6728 year: 2020 end-page: 6738 ident: bib42 article-title: Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization publication-title: J Clin Invest contributor: fullname: Zhao – volume: 5 start-page: 1 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib10 article-title: A systematic review and meta-analysis of cancer patients affected by a novel coronavirus publication-title: JNCI Cancer Spectr doi: 10.1093/jncics/pkaa102 contributor: fullname: Venkatesulu – volume: 10 start-page: 1 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib40 article-title: T-cell response after first dose of BNT162b2 SARS-CoV-2 vaccine among healthcare workers with previous infection or cross-reactive immunity publication-title: Clin Transl Immunol doi: 10.1002/cti2.1341 contributor: fullname: Casado – year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib35 article-title: Rapid induction of antigen-specific CD4+ T cells guides coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination publication-title: bioRxiv contributor: fullname: Painter – volume: 384 start-page: 403 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib3 article-title: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa2035389 contributor: fullname: Baden – volume: 60 start-page: 58 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib33 article-title: SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors publication-title: Breast (Edinburgh, Scotland) doi: 10.1016/j.breast.2021.08.017 contributor: fullname: Zagouri – volume: 181 start-page: 1489 year: 2020 ident: 10.1016/j.ejca.2022.02.017_bib27 article-title: Targets of T Cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals publication-title: Cell doi: 10.1016/j.cell.2020.05.015 contributor: fullname: Grifoni – year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib32 article-title: Immune responses to COVID-19 mRNA vaccines in patients with solid tumors on active, immunosuppressive cancer therapy publication-title: medRxiv: Preprint Server for Health Sciences contributor: fullname: Shroff – volume: 384 start-page: 2187 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib5 article-title: Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2101544 contributor: fullname: Sadoff – start-page: 1053 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib14 article-title: Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors publication-title: Ann Oncol: Off J Eur Soc Med Oncol doi: 10.1016/j.annonc.2021.04.019 contributor: fullname: Barrière – year: 2020 ident: 10.1016/j.ejca.2022.02.017_bib1 – volume: 39 start-page: 1034 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib22 article-title: Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer publication-title: Cancer Cell doi: 10.1016/j.ccell.2021.07.016 contributor: fullname: Ehmsen – volume: 139 start-page: 43 year: 2020 ident: 10.1016/j.ejca.2022.02.017_bib9 article-title: Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies publication-title: Eur J Cancer (Oxford, England: 1990) doi: 10.1016/j.ejca.2020.08.011 contributor: fullname: Saini – volume: 6 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib37 article-title: SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees publication-title: Sci Immunol doi: 10.1126/sciimmunol.abj1750 contributor: fullname: Geers – volume: 21 start-page: 39 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib7 article-title: Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(20)30831-8 contributor: fullname: Xia – volume: 157 start-page: 124 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib18 article-title: Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy - a single centre prospective study publication-title: Eur J Cancer (Oxford, England: 1990) doi: 10.1016/j.ejca.2021.08.007 contributor: fullname: Shmueli – volume: 32 start-page: S1129 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib39 article-title: 1557O Adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients: the CAPTURE study publication-title: Ann Oncol doi: 10.1016/j.annonc.2021.08.1550 contributor: fullname: Shepherd – volume: 397 start-page: 99 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib4 article-title: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK publication-title: Lancet doi: 10.1016/S0140-6736(20)32661-1 contributor: fullname: Voysey – volume: 39 start-page: 1091 issue: 8 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib13 article-title: Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer publication-title: Cancer Cell doi: 10.1016/j.ccell.2021.06.009 contributor: fullname: Addeo – volume: 2 start-page: 100355 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib26 article-title: Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals publication-title: Cell Rep Med doi: 10.1016/j.xcrm.2021.100355 contributor: fullname: Tarke – volume: 27 start-page: 568 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib34 article-title: COVID-19 vaccination: the VOICE for patients with cancer publication-title: Nat Med doi: 10.1038/s41591-021-01240-w contributor: fullname: van der Veldt – start-page: 799 year: 2020 ident: 10.1016/j.ejca.2022.02.017_bib8 article-title: Effect of cancer on clinical outcomes of patients with COVID-19: a meta-analysis of patient data publication-title: JCO Global Oncology doi: 10.1200/GO.20.00225 contributor: fullname: Giannakoulis – start-page: 86 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib19 article-title: Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors publication-title: J Hematol Oncol doi: 10.1186/s13045-021-01099-x contributor: fullname: Terpos – volume: 39 start-page: 257 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib24 article-title: Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients publication-title: Cancer Cell doi: 10.1016/j.ccell.2021.01.001 contributor: fullname: Abdul-Jawad – volume: 27 start-page: 2002 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib21 article-title: Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors publication-title: Nat Med doi: 10.1038/s41591-021-01542-z contributor: fullname: Shroff – volume: 7 start-page: 1 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib38 article-title: Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection publication-title: Sci Adv doi: 10.1126/sciadv.abg4081 contributor: fullname: Yatim – start-page: 579 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib12 article-title: The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate publication-title: Ann Oncol: Off J Eur Soc Med Oncol doi: 10.1016/j.annonc.2021.01.068 contributor: fullname: Garassino – volume: 584 start-page: 457 year: 2020 ident: 10.1016/j.ejca.2022.02.017_bib28 article-title: SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls publication-title: Nature doi: 10.1038/s41586-020-2550-z contributor: fullname: Le Bert – volume: 11 start-page: 233 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib11 article-title: Priority Covid-19 vaccination for patients with cancer while vaccine supply is limited publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-20-1817 contributor: fullname: Ribas – volume: 162 start-page: 182 year: 2022 ident: 10.1016/j.ejca.2022.02.017_bib43 article-title: Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: should humoral responses be monitored? A position article publication-title: Eur J Cancer (Oxford, England: 1990) doi: 10.1016/j.ejca.2021.12.011 contributor: fullname: Barrière – volume: 22 start-page: 765 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib20 article-title: Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(21)00213-8 contributor: fullname: Monin – volume: 397 start-page: 671 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib6 article-title: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia publication-title: Lancet (London, England) doi: 10.1016/S0140-6736(21)00234-8 contributor: fullname: Logunov – volume: 60 year: 2022 ident: 10.1016/j.ejca.2022.02.017_bib29 article-title: Evaluation of commercial anti-SARS-CoV-2 antibody assays and comparison of standardized titers in vaccinated health care workers publication-title: J Clin Microbiol doi: 10.1128/JCM.01746-21 contributor: fullname: Saker – volume: 157 start-page: 441 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib15 article-title: COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: seropositivity and safety. A prospective observational study in Italy publication-title: Eur J Cancer doi: 10.1016/j.ejca.2021.08.035 contributor: fullname: Cavanna – volume: 383 start-page: 2603 year: 2020 ident: 10.1016/j.ejca.2022.02.017_bib2 article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa2034577 contributor: fullname: Polack – volume: 6 start-page: 100274 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib17 article-title: Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment publication-title: ESMO Open doi: 10.1016/j.esmoop.2021.100274 contributor: fullname: Peeters – volume: 7 start-page: 1507 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib23 article-title: Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2021.2675 contributor: fullname: Goshen-Lago – volume: 150 start-page: 1 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib25 article-title: Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients publication-title: Eur J Cancer (Oxford, England: 1990) doi: 10.1016/j.ejca.2021.03.033 contributor: fullname: Mansi – volume: 160 start-page: 243 year: 2022 ident: 10.1016/j.ejca.2022.02.017_bib31 article-title: Immunogenicity and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after coronavirus disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis publication-title: Eur J Cancer (Oxford, England: 1990) doi: 10.1016/j.ejca.2021.10.014 contributor: fullname: Becerril-Gaitan – volume: 22 start-page: 581 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib41 article-title: Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors publication-title: Lancet Oncol doi: 10.1016/S1470-2045(21)00155-8 contributor: fullname: Waissengrin – volume: 7 start-page: 1133 year: 2021 ident: 10.1016/j.ejca.2022.02.017_bib16 article-title: Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2021.2155 contributor: fullname: Massarweh – volume: 33 start-page: 158 year: 2022 ident: 10.1016/j.ejca.2022.02.017_bib30 article-title: Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review publication-title: Ann Oncol: Off J Eur Soc Med Oncol doi: 10.1016/j.annonc.2021.10.014 contributor: fullname: Corti – volume: 21 start-page: 1336 year: 2020 ident: 10.1016/j.ejca.2022.02.017_bib36 article-title: Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 publication-title: Nat Immunol doi: 10.1038/s41590-020-0782-6 contributor: fullname: Peng – volume: 130 start-page: 6728 year: 2020 ident: 10.1016/j.ejca.2022.02.017_bib42 article-title: Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization publication-title: J Clin Invest doi: 10.1172/JCI141206 contributor: fullname: Salazar |
SSID | ssj0007840 |
Score | 2.4995878 |
Snippet | Patients with cancer (PC) are at high risk of acquiring COVID-19 and can develop more serious complications. Deeper understanding of vaccines immunogenicity in... Introduction Patients with cancer (PC) are at high risk of acquiring COVID-19 and can develop more serious complications. Deeper understanding of vaccines... |
SourceID | pubmedcentral proquest crossref pubmed elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 229 |
SubjectTerms | 2019-nCoV Vaccine mRNA-1273 Antibodies, Viral Cancer Cancer therapies Cancer vaccines CD4 antigen CD8 antigen Cellular response Chemotherapy Complications Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - adverse effects Cyclin-dependent kinases Dosage Health care Humans Humoral response Immune response (humoral) Immunization Immunogenicity Immunoglobulin G Immunotherapy Kinases Lymphocytes Lymphocytes T Medical personnel mRNA mRNA Vaccines Neoplasms - therapy Original Research Patients Prospective Studies Safety SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Solid tumors Solid tumours Tumors Vaccination Vaccines Vaccines, Synthetic |
Title | Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments |
URI | https://dx.doi.org/10.1016/j.ejca.2022.02.017 https://www.ncbi.nlm.nih.gov/pubmed/35316750 https://www.proquest.com/docview/2669597967/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC8885286 |
Volume | 166 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwEB5BkRAXtCyPLQvIh70h09ixU-dYVYsKiB4oIG6W7TqiSNuiNnDkt-NJnGq7rDgg5dK4I1meyfjTPL4B-CUyl3hRKBpsV1FE4NQYX1DLfcCvzuRFNWziepgN7sTlg3xYg37TC4NlldH31z698tbxTSeeZud5MumMMIKlAsDlvMrvyHXYCNeREC3Y6F1cDYZLh9xVVV9kHfEKArF3pi7z8k8O6Yc4r6g7q7ll_72fPuLPf8so_7qXzr_BdgSUpFfveQfW_PQ7bF7HlPkuLGILE7klGKQn87oo1pNyRka9mxHtz-4pJ39uhj3yahwKkWoCEYmUqwuCsVri0DzmQdz5CQYhSDNapWyWljXriz24O_992x_QOGmBOqHSkjLHODdjI8cmT8YCs3fcODsWjBmZ2nDC1gRw5L2TltlcGuGlsUmaSpMxx9N0H1rT2dT_AOJT45PM-8IxzKranPGCuQAjCkxAGtaG0-Z89XNNqKGbSrMnjdrQqA2dhId12yAbFegVs9DB438qd9ToS8ePcqEDFgkm0M2zsHxQq265hVQiJYBM2tBdUeryD0jDvboynTxWdNxKKclVdvjFrf6ELfxVF1EeQaucv_jjAHRKewLrZ2_sJJrzO0Z__Ww |
link.rule.ids | 230,315,786,790,891,4521,24144,27957,27958,45620,45714 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCa6Dth2Kbquj_Sx6tDboMWSLUc-BkGLbGtyaNKhN0FSZDQFmhSJt-N-e0VZTpuu2GGAT6YECCJNfyA_kgBnWW4Tl5WSetuVFBE41dqV1HDn8avVRRmGTQyGef86-34jbjag19TCIK0y-v7apwdvHd-04222H6bT9ggjWNIDXM5Dfke8gbcI53F-w9c_TzyPjgxVkXW8yy-PlTM1ycvdWWw-xHlo3Bmmlr36d_obfb4kUT77K11sw1aEk6Rbn_gjbLjZDrwbxIT5J1jGAiYyJhiiJ4uaEutINSej7tWI9uY_KSf3V8Mu-a0tbiJh_hCJDVeXBCO1xKJxLPx266YYgiDNYJWqEa0Y68tduL44H_f6NM5ZoDaTaUWZZZzriRYTXSSTDHN3XFszyRjTIjX-fo320Mg5KwwzhdCZE9okaSp0zixP0z3YnM1n7gCIS7VLcudKyzCnagrGS2Y9iCgx_ahZC74096se6nYaquGZ3SnUhkJtqMQ_rNMC0ahArRmF8v7-n_uOG32p-EkulUci3gQ6Re7F-7XqVkdIBTYEEEkLOmtKXS3AJtzrktn0NjTjllIKLvPD_zzqKbzvjweX6vLb8McRfEBJTac8hs1q8cudeMhTmc_BpB8Bdd_-Og |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Limited+T+cell+response+to+SARS-CoV-2+mRNA+vaccine+among+patients+with+cancer+receiving+different+cancer+treatments&rft.jtitle=European+journal+of+cancer+%281990%29&rft.au=Cort%C3%A9s%2C+Alfonso&rft.au=Casado%2C+Jos%C3%A9+L&rft.au=Longo%2C+Federico&rft.au=Serrano%2C+Juan+J&rft.date=2022-05-01&rft.eissn=1879-0852&rft.volume=166&rft.spage=229&rft_id=info:doi/10.1016%2Fj.ejca.2022.02.017&rft_id=info%3Apmid%2F35316750&rft.externalDocID=35316750 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0959-8049&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0959-8049&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0959-8049&client=summon |